<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1271" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="737" end="742"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="846" end="858"/>
    <type:OSMean xmi:id="21" sofa="6" begin="911" end="922"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Combination of capecitabine and irinotecan (XELIRI regimen) is an&#13;&#10;active and well tolerated treatment for metastatic colorectal cancer (mCRC). The &#13;&#10;aim of this study was to evaluate the efficacy and safety of this regimen in&#13;&#10;combination with bevacizumab (BV), as first-line treatment for mCRC.&#13;&#10;PATIENTS AND METHODS: A total of 46 consecutive patients received a combination&#13;&#10;of BV (5?mg?kg?¹, day 1), irinotecan (175?mg?m?², day 1) and capecitabine&#13;&#10;(1000?mg?m?² twice daily on day 2-8), every 2 weeks. Patients were treated until &#13;&#10;disease progression or unacceptable toxicity. The primary objective was to&#13;&#10;determine the progression-free survival (PFS) and safety profile.&#13;&#10;RESULTS: The overall response rate (ORR) was 67.4%, with a disease control rate&#13;&#10;(ORR+stable disease) of 93.5%. Median PFS and overall survival (OS) were 12.3&#13;&#10;months (95% confidence interval (CI): 6.5-18.1 months) and 23.7 months (95% CI:&#13;&#10;16.7-30.6 months), respectively. The most frequent grade 3/4 treatment-related&#13;&#10;adverse events were asthenia (7%), diarrhoea (7%), nausea (9%) and vomiting (7%).&#13;&#10;CONCLUSION: Bevacizumab combined with biweekly XELIRI is a highly active&#13;&#10;first-line regimen for mCRC treatment, showing encouraging PFS, ORR and OS with a&#13;&#10;good tolerability."/>
    <cas:View sofa="6" members="1 13 17 21"/>
</xmi:XMI>
